The amino-terminal fragment of the B-type natriuretic peptide prohormone (NT-proBNP) is a marker for functional cardiac impairment and is increased in heart disease with or without symptoms of heart failure (HF) (1 ) . There are indications that currently used assays for NTproBNP may differ in their cross-reactivity with circulating NT-proBNP split products and may also be affected by breakdown products of NT-proBNP produced after blood collection (2 ) . A newer generation assay, a commercially available competitive enzyme immunoassay (EIA) for NT-proBNP (Biomedica Gruppe) (3 ) that does not require sample pretreatment, has been used in various methodologic and clinical studies (4 -6 ) , but noncompetitive immunoassays may offer advantages of better speed, sensitivity, precision, and possibly specificity over competitive immunoassays (7 ) . Recently, a noncompetitive immunoassay for NT-proBNP has been developed (8 ) . A fully automated version of this assay (Roche Diagnostics) has now been cleared by the US Food and Drug Administration. Our aim was to compare the Biomedica and Roche NT-proBNP assays, addressing whether the predictive values of both assays are similar with respect to structural heart disease with or without symptoms of HF.
The present study, carried out at the Division of Internal Medicine, St. John of God Hospital (Linz, Austria), was approved by the local ethics committee in accordance to the Helsinki Declaration. We prospectively recruited 157 consecutive patients admitted for extensive cardiac evaluation (including performance of bicycle ergometry) and 23 consecutive patients with symptomatic HF admitted for inpatient treatment; all participants gave written informed consent. Study participants were classified according to the American College of Cardiology/American Heart Association guidelines for the evaluation and management of chronic HF in the adults (9 ) to one of the four following categories: (a) healthy individuals (n ϭ 42); (b) patients at high risk for developing HF but without structural disorders of the heart (HF stage A; n ϭ 39); (c) patients with structural disorders of the heart but without symptoms of HF (HF stage B; n ϭ 56); and (d) patients with past or current symptoms of HF associated with underlying structural heart disease (HF stage C; n ϭ 43). None of the study participants belonged to HF stage D according to the above guidelines (patients with end stage disease requiring specialized treatment strategies). This classification was done by one experienced cardiologist (one of the investigators) blinded to the NT-proBNP results and was based on detailed anamnesis with evaluation of the patients' medical reports, appropriate risk factor assessment, physical examination, 12-lead electrocardiography, chest radiography, two-dimensional echocardiography coupled with Doppler flow studies, bicycle ergometry (in the 157 consecutive patients admitted for extensive cardiac evaluation), and an ongoing assessment of the patients' clinical status. Normal echocardiographic findings (i.e., individuals without structural disorders of the heart) were defined by a left ventricular end-diastolic diameter Ͻ56 mm without left ventricular hypertrophy or without wall motion abnormities, a right ventricular systolic pressure Ͻ35 mmHg, and a left ventricular ejection fraction Ͼ60%. No attempt was made to define diastolic HF. Drug therapy (i.e., angiotensin-converting enzyme inhibitors, beta-blockers, digitalis, and diuretics) was recorded at the day of blood collection and was modified in the sequel. The demographic and clinical characteristics of the study participants are listed in Table  1 .
Blood for measurement of NT-proBNP concentrations was collected by venipuncture in Vacuette ® polyethylene terephthalate glycol clot activator tubes (Greiner Bio-One) after an overnight fast, with the study participants in supine position for at least 20 min. Serum was separated for each assay. Roche NT-proBNP assays were done within 4 h after specimen collection on a Roche Elecsys 2010 analyzer. Samples for the Biomedica NT-proBNP assay were stored at Ϫ70°C until analysis (up to 12 weeks of storage). Both assays were performed according to the manufacturers' recommendations.
The Biomedica assay is a competitive EIA designed to measure immunoreactive NT-proBNP in diluted human serum or plasma. The assay incorporates a purified polyclonal sheep antibody specific for NT-proBNP (amino acids 8 -29) immobilized to the surface of a microtiter plate well. The Roche test is a noncompetitive EIA (chemiluminescent technology) for the determination of NTproBNP in human serum and plasma (possible anticoagulants are lithium and ammonium heparin or tripotassium EDTA). This is a two-site (sandwich) assay incorporating a biotinylated polyclonal NT-proBNP-specific (amino acids 1-21) antibody and a polyclonal NT-proBNP-specific (amino acids 39 -50) antibody labeled with a ruthenium complex.
For the Biomedica assay, the within-run CVs were 9.9% [mean concentration (MC), 236 pmol/L; n ϭ 20] and 11% (MC, 550 pmol/L; n ϭ 20), respectively, for low-and high-concentration patient samples, and the respective day-to-day CVs were 11% (MC, 238 pmol/L; n ϭ 6) and 13% (MC, 519 pmol/L; n ϭ 6). For the Roche assay, the within-run CVs were 4.6% (MC, 5.6 pmol/L; n ϭ 20) and 1.9% (MC, 107.5 pmol/L; n ϭ 20), respectively, for lowand high-concentration patient samples, and the respective day-to-day CVs were 5.5% (MC, 6.4 pmol/L; n ϭ 20) and 2.6% (MC, 113.6 pmol/L; n ϭ 20). Calculation of day-to-day CVs was based on a single calibration for the Roche assay and on multiple calibrations for the Biomedica assay.
Statistical analysis was performed with the MedCalc package for Windows (Ver. 7.0.0.3). Because NT-proBNP values of the 180 study participants were skewed rightward, NT-proBNP values were compared with use of the Wilcoxon signed-rank test. Passing & Bablok regression (Fig. 1A) revealed an intercept of 20.1 pmol/L [95% confidence interval (95% CI), 3.7-40.0 pmol/L] and slope of 8.4 (95% CI, 6.4 -10.9), suggesting a constant and a proportional difference between the two methods. The cusum test showed a significant deviation from linearity (P Ͻ0.01). The BlandAltman difference plot (Fig. 1B) showed a large mean difference between NT-proBNP measurements (Ϫ224 pmol/L) and indicated a concentration-dependent negative difference. A percentage difference plot (not shown) also revealed a large systematic error for NT-proBNP measurements with a mean difference of Ϫ153% and with wide 95% limits of agreement of Ϫ75% and Ϫ230%. In distinguishing between patients with symptomatic HF (HF stage C; n ϭ 43) and individuals without HF (n ϭ 137; 81 individuals without disorders of the heart and 56 patients with asymptomatic structural heart disease), the AUCs were 0.918 (SE, 0.030; 95% CI, 0.868 -0.954) for the Roche assay and 0.866 (SE, 0.037; 95% CI, 0.807-0.912) for the Biomedica assay. This difference was not statistically significant (P ϭ 0.116). Under these conditions, the cutoff values with the highest diagnostic accuracy were 24.9 pmol/L for the Roche method [sensitivity, 93% (95% CI, 81-99%); specificity, 82% (95% CI, 74 -88%)] and 374 pmol/L for the Biomedica method [sensitivity, 70% (95% CI, 54 -83%); specificity, 92% (95% CI, 86 -96%)].
We observed enhanced AUC differences when we compared the diagnostic utility of both tests with respect to asymptomatic structural heart disease (56 patients with HF stage B compared with 81 individuals without structural disorder of the heart). The Roche assay had an AUC of 0.839 (SE, 0.037; 95% CI, 0.767-0.896), and the Biomedica assay had an AUC of 0.673 (SE, 0.048; 95% CI, 0.588 -0.751), with the difference being statistically significant (P ϭ 0.001). Optimal cutoff values for the detection of HF stage B were 8.28 pmol/L for the Roche method [sensitivity, 80% (95% CI, 68 -90%); specificity, 77% (95% CI, 66 -85%)] and 191 pmol/L for the Biomedica method [sensitivity, 55% (95% CI, 42-69%); specificity, 82% (95% CI, 71-89%)].
The major finding of our study was a considerable lack of agreement between the Roche and Biomedica methods. Direct comparison revealed a large systematic difference between the two methods, and there was a consistent tendency for results obtained with the Biomedica method to be higher than those obtained with the Roche method, with the difference increasing with increasing concentrations. Hence, both methods differed substantially with respect to the observed NT-proBNP values. Given the hypothesis that both NT-proBNP split products and the intact NT-proBNP molecule are present in the circulation (2 ), our observations may be attributable to the different epitopes detected by both assays. The Biomedica assay uses a single antibody against the N-terminal region of NT-proBNP (amino acids 8 -29), whereas the Roche assay antibodies are designed to recognize the N-terminal region (amino acids 1-21) and the midregion of NT-proBNP (amino acids 39 -50), thus detecting larger fragments of NT-proBNP.
Both the Roche and Biomedica assays may, however, be useful as diagnostic aids in symptomatic HF (HF stage C), as indicated by comparable AUCs in the ROC analysis.
Higher cutoff values for the Biomedica assay have to be considered, compared with the Roche assay. In contrast, the Biomedica assay seems to be less useful than the Roche assay for the detection of asymptomatic structural heart disease (HF stage B). Because more discrete differences in NT-proBNP values need to be distinguished for HF stage B, the lower sensitivity and specificity of the Biomedica assay for diagnosis of this stage may be a consequence of the greater imprecision of the competitive Biomedica NT-proBNP method compared with the noncompetitive sandwich assay from Roche. Theoretically, the presence of various NT-proBNP split products, possibly having different biological activities and metabolic pathways, may also contribute to this phenomenon. However, the underlying mechanisms remain unclear.
Limitations of our study include the hospital-based study design, the fact that the prevalence of each HF class may have been fixed by the selection of participants (possibly not representative of routine practice), the wide age range not equally distributed among the study groups, and the greater tendency for diseased patients to be receiving drug therapy. These facts may have imposed a certain bias related to the absolute sizes of the AUCs in the ROC analysis. However, the relative proportions of the AUCs for the two methods, showing that the Biomedica and the Roche assays give comparable information for diagnosis of HF stage C and that the Roche assay might be superior to the Biomedica test for diagnosis of HF stage B, should not be affected by the above limitations. Further comparisons of the newer NT-proBNP assays, tested by independent research laboratories and considering hospital as well as general practice settings, are necessary to thoroughly clarify both their analytical performance and their potential clinical utility. Blood dried on filter paper is widely used for screening of inherited metabolic disorders (1 ). In Sweden, such filters from all newborns have been permanently stored since 1975. It has been shown that proteins and DNA may be recovered from these cards after extended periods of storage (2) (3) (4) . RNA, however, has been considered too vulnerable to degradation by ribonucleases to be recovered from these filters. Despite this, Zhang and McCabe (5 ) and Matsubara et al. (6 ) reported that mRNA could be isolated from such filters after up to 4 years of storage. The stability of viral RNA on filters has also been reported (7, 8 ) , although this was not tested over extended periods of time. The purpose of the present study was to investigate whether RNA could be recovered from filters that had been stored since 1975 and be amplified by reverse transcription-PCR.
Extraction
After approval by the local ethics committee, we randomly selected filter papers (specimen collection paper 2992; Schleicher & Schuell) that had been stored for 1 month, 21 years, and 27 years; for each time point, we selected five filters. One-fourth of a spot (ϳ0.3 cm 2 ) containing dried blood was cut out of each filter with a sterile razor blade. As a negative control, a piece of corresponding size was cut from a blood-free area of each filter. RNA was isolated from the specimen with use of the RNeasy reagent set (Qiagen) according to the manufacturer's instructions. Briefly, filters were incubated in lysis buffer at 37°C for 30 min in a thermomixer (Eppen-
